Olive Oil Activated the GLP-1 Pathway in a Controlled Trial

Why This Study Matters

GLP-1 receptor agonists -- semaglutide (Ozempic), liraglutide (Victoza), tirzepatide (Mounjaro) -- are among the most prescribed drugs in the world right now. They work by mimicking GLP-1, a hormone that regulates blood sugar and appetite. The pharmaceutical approach is to flood the body with synthetic GLP-1 at doses far beyond what the body produces naturally.

This 2015 study from Sapienza University of Rome asked a different question: can a food -- specifically, extra virgin olive oil -- influence the body's own GLP-1 system? And if so, through what mechanism?

The researchers, led by Francesco Violi and colleagues at the Department of Internal Medicine and Medical Specialties, ran a randomized crossover trial in 25 healthy subjects. They found that a single meal containing 10 grams of EVOO significantly increased GLP-1, decreased DPP-4 activity (the enzyme that breaks down GLP-1), and lowered post-prandial blood glucose compared to the same meal made with corn oil.

This is a small, acute study -- 25 people, one meal, measured over two hours. It does not demonstrate chronic metabolic effects, weight loss, or anything close to what GLP-1 agonist drugs achieve. What it does demonstrate is a specific biochemical mechanism linking olive polyphenols to incretin signaling, measured in a controlled setting.

How It Was Designed

The trial was structured as two separate sub-studies, both using a randomized crossover design. In a crossover trial, each participant receives both the intervention and the control at different times, separated by a washout period. This means each person serves as their own control -- an important strength when sample size is small, because it eliminates between-person variability.

Sub-study 1 compared a Mediterranean-type lunch containing 10 g of EVOO against the same lunch with 10 g of corn oil. Sub-study 2 compared a Mediterranean-type lunch with 10 g of EVOO against the same lunch with no added oil. Blood was drawn at baseline (fasting) and again two hours after the meal.

The comparison to corn oil is worth noting. Corn oil has a similar caloric and fat content but a much lower polyphenol concentration than EVOO. This means the study was not simply comparing fat vs. no fat, or calories vs. no calories. It was comparing a high-polyphenol oil against a low-polyphenol oil with a similar macronutrient profile. Differences in outcomes can more reasonably be attributed to the polyphenol content rather than the fat itself.

The study was published in Nutrition & Diabetes (volume 5, issue 7, e172) on July 20, 2015.

What They Found

Two hours after the meal, the EVOO condition showed significant differences from the corn oil and no-oil conditions across several biomarkers:

Biomarker	EVOO Meal	Control / Corn Oil	p-value	What It Measures
Blood glucose	Significantly reduced	Higher post-prandial rise	< 0.001	Post-meal blood sugar
GLP-1	Increased	Lower / no change	< 0.01	Incretin hormone (glucose regulation)
DPP-4 activity	Decreased	No significant change	< 0.05	Enzyme that degrades GLP-1
LDL cholesterol	Reduced post-prandially	No significant change	< 0.05	Low-density lipoprotein
Oxidized LDL	Reduced	No significant change	< 0.05	Oxidative damage to LDL particles
GIP	Increased	Lower response	< 0.05	Glucose-dependent insulinotropic polypeptide

Green indicates a favorable direction vs. control. All differences reported reached statistical significance.

Reading the Results

The findings group into two areas:

Glucose regulation (blood glucose, GLP-1, DPP-4, GIP). The central finding is a two-part mechanism. EVOO increased GLP-1 -- the incretin hormone that signals the pancreas to release insulin in response to food. At the same time, it decreased DPP-4 activity. DPP-4 is the enzyme that rapidly degrades GLP-1 in the bloodstream; DPP-4 inhibitors (sitagliptin, saxagliptin, and others) are an entire class of diabetes drugs that work by blocking this enzyme. The net effect: more GLP-1 produced, and less of it broken down. Blood glucose after the meal was significantly lower in the EVOO condition. GIP, a second incretin hormone, also increased with EVOO, reinforcing the incretin pathway finding.

Lipid effects (LDL, oxidized LDL). Post-prandial LDL cholesterol decreased after the EVOO meal compared to control. Oxidized LDL -- the form of LDL that is more directly involved in atherosclerotic plaque formation -- also decreased. These are acute, post-meal measurements, not chronic changes in lipid profiles. But they are consistent with prior research on olive polyphenols and lipid oxidation, including the mechanism recognized by the European Food Safety Authority's 2011 health claim for olive oil polyphenols.

What Didn't Change

Insulin levels did not differ significantly between conditions. HDL cholesterol and triglycerides showed no significant post-prandial differences. DPP-4 protein concentration (as opposed to DPP-4 activity) also did not change -- EVOO appeared to inhibit the enzyme's function without altering how much of it was present.

The most important limitation is scope. This was a single-meal study in 25 healthy subjects. It measured what happened over two hours, not two months. The participants were healthy -- not diabetic, not prediabetic, not dyslipidemic. Whether these acute effects translate to sustained metabolic improvements with regular EVOO consumption is a separate question that this study does not answer.

The study also used whole EVOO, not an isolated polyphenol extract. The researchers attributed the effects to the polyphenol content based on the corn oil comparison, but EVOO contains hundreds of bioactive compounds. The specific contribution of any single polyphenol -- hydroxytyrosol, oleuropein, oleocanthal -- cannot be determined from this design.

Broader Context

The GLP-1 pathway has become one of the most important targets in metabolic medicine. Semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro) are synthetic GLP-1 receptor agonists administered by injection at pharmacological doses. DPP-4 inhibitors like sitagliptin (Januvia) are oral drugs that prevent GLP-1 degradation. Together, these drug classes represent tens of billions of dollars in annual sales.

This study does not suggest that olive oil replaces those drugs. The scale is entirely different -- a single meal with 10 grams of EVOO produces a modest, transient increase in endogenous GLP-1, while injectable semaglutide delivers sustained receptor activation at supraphysiological levels. The clinical outcomes are not comparable.

What this study does provide is mechanistic evidence that dietary polyphenols can interact with the incretin system at a biochemical level. That is a meaningful finding for understanding how traditional dietary patterns -- particularly the Mediterranean diet -- may contribute to metabolic health through specific, measurable pathways rather than vague "antioxidant" effects.

In 2011, the European Food Safety Authority (EFSA) authorized a health claim for olive oil polyphenols and the protection of blood lipids from oxidative damage. The LDL and oxidized LDL findings in this study are consistent with that recognized mechanism. The GLP-1 findings point to a separate, additional pathway that was less well characterized at the time of the EFSA opinion.

Related Research

Continue exploring olive oil and polyphenol science:

• Hydroxytyrosol-Enriched Bread Improved HbA1c in T2D Adults
• Hydroxytyrosol Improves 7 Biomarkers of Aging and Inflammation
• The Lipidome Score: How Replacing Saturated Fat Cuts CV and T2D Risk

Source: View the original study on PubMed

Olivea's Dosage

This study used whole extra virgin olive oil -- not isolated hydroxytyrosol or a polyphenol extract. The effects were attributed to the polyphenol content of EVOO based on the comparison to corn oil, but the exact polyphenol dose was not standardized or reported as a standalone figure. Each Olivea capsule delivers a standardized dose of hydroxytyrosol, the primary polyphenol in EVOO. Our most recent third-party certificate of analysis confirmed 23.5 mg per capsule.

Because this study tested whole EVOO rather than an isolated compound, direct dosage comparisons to a hydroxytyrosol supplement are not appropriate. We include this study in our research library because it demonstrates a specific mechanism -- polyphenol-mediated incretin signaling -- that is relevant to the broader science of olive-derived compounds.

We share this research for transparency. This is an independent study -- we did not fund it, design it, or conduct it.

Editorial Information

Research note. This article summarizes third-party research published in a peer-reviewed journal. Olivea did not conduct or fund the study. Findings reflect the cited paper only and do not establish efficacy of Olivea products.

.